| Diabetes Mellitus, Non-Insulin-Dependent
Steglujan vs Victoza
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Steglujan vs Victoza with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVictoza has a higher rate of injection site reactions vs Steglujan based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Victoza but not Steglujan, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Steglujan
Victoza
At A Glance
Oral
Once daily
SGLT2 inhibitor + DPP-4 inhibitor
SC injection
Daily
GLP-1 receptor agonist
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
- Cardiovascular Diseases
Dosing
Diabetes Mellitus, Non-Insulin-Dependent Starting dose 5 mg ertugliflozin/100 mg sitagliptin orally once daily in the morning, with or without food; may increase to 15 mg/100 mg once daily for additional glycemic control; not recommended if eGFR less than 45 mL/min/1.73 m2; withhold at least 4 days before surgery or procedures associated with prolonged fasting.
Diabetes Mellitus, Non-Insulin-Dependent, Cardiovascular Diseases (Adults) Start at 0.6 mg SC once daily for one week, then increase to 1.2 mg once daily; if additional glycemic control is required, increase to 1.8 mg once daily (maximum) after at least one week at 1.2 mg.
Diabetes Mellitus, Non-Insulin-Dependent (Pediatric >= 10 years) Start at 0.6 mg SC once daily; increase in 0.6 mg increments after at least one week on the current dose; maximum recommended dose is 1.8 mg once daily.
Contraindications
- Severe renal impairment (eGFR less than 30 mL/min/1.73 m2), end-stage renal disease (ESRD), or on dialysis
- Hypersensitivity to sitagliptin, ertugliflozin, or any excipient in STEGLUJAN
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Serious hypersensitivity reaction to liraglutide or any excipient in VICTOZA
Adverse Reactions
Most common (>=2%) Female genital mycotic infections, male genital mycotic infections, urinary tract infections, headache, vaginal pruritus, increased urination, nasopharyngitis, back pain, weight decreased, thirst
Serious Diabetic ketoacidosis, pancreatitis, lower limb amputation, acute renal failure, volume depletion, urosepsis and pyelonephritis, heart failure, hypoglycemia (with insulin or insulin secretagogues), necrotizing fasciitis of the perineum (Fournier's Gangrene), hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid
Postmarketing Necrotizing fasciitis of the perineum, angioedema, rash, anaphylaxis, urticaria, cutaneous vasculitis, Stevens-Johnson syndrome, pruritus, hepatic enzyme elevations, acute pancreatitis, worsening renal function, severe and disabling arthralgia, myalgia, rhabdomyolysis
Most common (>=5%) Nausea, diarrhea, headache, nasopharyngitis, vomiting, decreased appetite, dyspepsia, upper respiratory tract infection, constipation, back pain
Serious Risk of thyroid C-cell tumors, acute pancreatitis, hypoglycemia, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions, acute gallbladder disease, pulmonary aspiration during general anesthesia or deep sedation
Postmarketing Acute pancreatitis, hemorrhagic and necrotizing pancreatitis, ileus, intestinal obstruction, severe constipation, dehydration, elevations of liver enzymes, hyperbilirubinemia, cholestasis, cholecystitis, cholelithiasis, hepatitis, angioedema, anaphylactic reactions, pruritus, medullary thyroid carcinoma, dysgeusia, dizziness, dysesthesia, pulmonary aspiration, acute renal failure, increased serum creatinine, cutaneous amyloidosis, alopecia
Pharmacology
STEGLUJAN combines ertugliflozin, an SGLT2 inhibitor that reduces renal reabsorption of filtered glucose and increases urinary glucose excretion, and sitagliptin, a DPP-4 inhibitor that slows inactivation of incretin hormones (GLP-1 and GIP), thereby increasing insulin release and decreasing glucagon secretion in a glucose-dependent manner.
GLP-1 receptor agonist; liraglutide is an acylated human GLP-1 analog (97% amino acid sequence homology to endogenous human GLP-1(7-37)) that stimulates glucose-dependent insulin secretion, suppresses glucagon secretion, and delays gastric emptying.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Steglujan
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (7/12) · Qty limit (9/12)
Victoza
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Steglujan
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Victoza
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (5/8)
Humana
Steglujan
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Victoza
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Steglujan.
No savings programs available for Victoza.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SteglujanView full Steglujan profile
VictozaView full Victoza profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.